01—Abstract
Summary
Summary of the 8-K filed February 26, 2024. Cited figures are marked; the original filing is the authoritative source.
HCA Healthcare, Inc. (HCA) filed an 8-K on February 26, 2024, detailing its 2024 Executive Officer Performance Excellence Program (Executive Officer PEP).
This program establishes performance-based compensation for the company's executive officers, with awards weighted 80%a on EBITDA targets and 20% on quality metrics. Specific EBITDA targets will be set for the company overall and for key operating groups, while quality metrics will focus on Healthcare-Associated Infections and Sepsis, Complication and Mortality, and Care Experience. Furthermore, the filing announces an adjustment to the compensation for Michael R.
McAlevey, who will transition to Executive Vice President – Chief Legal and Administrative Officer on April 1, 2024. This transition includes a base salary increase and a significant long-term equity incentive award.
Notably, William B. Rutherford, Executive Vice President and Chief Financial Officer, will retire on May 1, 2024, and will not participate in the Executive Officer PEP.
02—Key points
Key Highlights
- HCA has implemented the 2024 Executive Officer Performance Excellence Program (PEP) to incentivize executive performance.
- Compensation under the PEP is 80% tied to EBITDA performance and 20% to quality metrics.
- Quality metrics include Healthcare-Associated Infections and Sepsis, Complication and Mortality, and Care Experience.
- Presidential awards have a dual weighting: 50% on company EBITDA and 50% on their respective group's EBITDA.
- CEO Samuel N. Hazen's target award opportunity is 170% of base salary; COO Jon M. Foster's is 125%; and SVP & Chief Legal Officer Michael R. McAlevey's is 85% (increasing to 100%).
- Michael R. McAlevey will be appointed Executive Vice President – Chief Legal and Administrative Officer effective April 1, 2024, with a new base salary of $990,000 and a $500,000 long-term equity incentive award.
- William B. Rutherford, CFO, plans to retire effective May 1, 2024, and will not participate in the 2024 Executive Officer PEP.
03—Questions
Frequently Asked Questions
What is the main purpose of the 2024 Executive Officer Performance Excellence Program (PEP)?
The Executive Officer PEP is designed to align executive compensation with the achievement of specific financial and operational performance targets, encouraging growth and quality improvement within HCA Healthcare.
How is executive compensation determined under the new PEP program?
Executive compensation under the PEP is primarily driven by performance. 80% of the award opportunity is based on achieving specified EBITDA targets (both company-wide and for specific groups), and the remaining 20% is based on meeting targets for key quality metrics.
What are the key quality metrics being tracked for executive compensation?
The quality metrics include Healthcare-Associated Infections and Sepsis (30% of quality portion), Complication and Mortality (30%), and Care Experience (40%).
What is the significance of Michael R. McAlevey's new role and compensation?
Michael R. McAlevey's appointment to Executive Vice President – Chief Legal and Administrative Officer, effective April 1, 2024, comes with an increased base salary and a substantial long-term equity incentive award, reflecting his expanded responsibilities. His target award opportunity under the PEP will also increase.
Will the CFO, William B. Rutherford, receive compensation under the 2024 PEP program?
No, William B. Rutherford intends to retire as CFO effective May 1, 2024, and therefore will not participate in the 2024 Executive Officer PEP.
04—Continue